A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer

References

• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–240. doi:10.3322/canjclin.22.4.232
   PubMedGoogle Scholar
• Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J. Androgen insensitivity syndrome. Lancet. 2012;380(9851):1419–1428. doi:10.1016/S0140-6736(12)60071-3
   PubMed Web of Science ®Google Scholar
• Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140(3):223–238. doi:10.1016/j.pharmthera.2013.07.003
   PubMed Web of Science ®Google Scholar
• Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20(13):3001–3015. doi:10.1200/JCO.2002.10.018
   PubMed Web of Science ®Google Scholar
• Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl. 2010;12(5):639–657. doi:10.1038/aja.2010.89
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR, et al; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. doi:10.1056/NEJMoa1702900
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Fizazi K, Saad F, et al; PROSPER Investigators. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23):2197–2206. doi:10.1056/NEJMoa2003892
   PubMed Web of Science ®Google Scholar
• Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion [published correction appears in Nat Clin Pract Urol. 2009 Mar;6(3):173]. Nat Clin Pract Urol. 2009;6(2):76–85. doi:10.1038/ncpuro1296
   PubMedGoogle Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–1038. doi:10.1056/NEJMoa1315815
   PubMed Web of Science ®Google Scholar
• Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4(6):380–384. doi:10.5489/cuaj.10167
   PubMed Web of Science ®Google Scholar
• Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013;190(2):429–438. doi:10.1016/j.juro.2013.05.005
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Hyytinen E, Koivisto P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9(4):401–406. doi:10.1038/ng0495-401
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 1999;59(4):803–806.
   PubMed Web of Science ®Google Scholar
• Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001;61:3550–3555.
   PubMed Web of Science ®Google Scholar
• Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016;7(39):64447–64470. doi:10.18632/oncotarget.10901
   PubMedGoogle Scholar
• Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33–39. doi:10.1038/nm972
   PubMed Web of Science ®Google Scholar
• Van der Steen T, Tindall DJ, Huang H. Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci. 2013;14(7):14833–14859. doi:10.3390/ijms140714833
   PubMed Web of Science ®Google Scholar
• Azad AA, Zoubeidi A, Gleave ME, Chi KN. Targeting heat shock proteins in metastatic castration- resistant prostate cancer. Nat Rev Urol. 2015;12:26–36. doi:10.1038/nrurol.2014.320
   PubMed Web of Science ®Google Scholar
• Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16–22. doi:10.1158/0008-5472.CAN-08-2764
   PubMed Web of Science ®Google Scholar
• Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68(13):5469–5477. doi:10.1158/0008-5472.CAN-08-0594
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197. doi:10.1056/NEJMoa1207506
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi:10.1056/NEJMoa1014618
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148. doi:10.1056/NEJMoa1209096
   PubMed Web of Science ®Google Scholar
• Armstrong CM, Gao AC. Current strategies for targeting the activity of androgen receptor variants. Asian J Urol. 2019;6(1):42–49. doi:10.1016/j.ajur.2018.07.003
   Web of Science ®Google Scholar
• Tan J, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol. 1997;11:450–459. doi:10.1210/mend.11.4.9906
   PubMed Web of Science ®Google Scholar
• Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701–711. doi:10.1038/nrc4016
   PubMed Web of Science ®Google Scholar
• Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki SJ. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate. 1996;29(3):153–158. doi:10.1002/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol. 1993;46(6):759–765. doi:10.1016/0960-0760(93)90316-O
   PubMed Web of Science ®Google Scholar
• Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994;54(11):2861–2864.
   PubMed Web of Science ®Google Scholar
• Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3(9):1020–1029. doi:10.1158/2159-8290.CD-13-0226
   PubMed Web of Science ®Google Scholar
• Coffey K, Robson CN. Regulation of the androgen receptor by post-translational modifications. J Endocrinol. 2012;215(2):221–237. doi:10.1530/JOE-12-0238
   PubMed Web of Science ®Google Scholar
• Wen S, Niu Y, Huang H. Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer. Asian J Urol. 2020;7(3):203–218. doi:10.1016/j.ajur.2019.11.001
   Web of Science ®Google Scholar
• Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev. 2014;40(3):426–433. doi:10.1016/j.ctrv.2013.09.011
   Web of Science ®Google Scholar
• Russo JW, Liu X, Ye H, et al. Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett. 2018;438:97–104. doi:10.1016/j.canlet.2018.09.014
   Web of Science ®Google Scholar
• McCall P, Adams CE, Willder JM, et al. Androgen receptor phosphorylation at serine 308 and serine 791 predicts enhanced survival in castrate resistant prostate cancer patients. Int J Mol Sci. 2013;14(8):16656–16671. doi:10.3390/ijms140816656
   PubMed Web of Science ®Google Scholar
• Qi J, Tripathi M, Mishra R, et al. The E3 ubiquitin ligase siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell. 2013;23(3):332–346. doi:10.1016/j.ccr.2013.02.016
   Web of Science ®Google Scholar
• Hermanson O, Glass CK, Rosenfeld MG. Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab. 2002;13(2):55–60. doi:10.1016/S1043-2760(01)00527-6
   Web of Science ®Google Scholar
• Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778–808.
   PubMed Web of Science ®Google Scholar
• Wolf IM, Heitzer MD, Grubisha M, DeFranco DB. Coactivators and nuclear receptor transactivation. J Cell Biochem. 2008;104(5):1580–1586. doi:10.1002/jcb.21755
   Web of Science ®Google Scholar
• Culig Z. Androgen receptor coactivators in regulation of growth and differentiation in prostate cancer. J Cell Physiol. 2016;231(2):270–274. doi:10.1002/jcp.25099
   Web of Science ®Google Scholar
• Feng Q, He B. Androgen receptor signaling in the development of castration-resistant prostate cancer. Front Oncol. 2019;9:858. doi:10.3389/fonc.2019.00858
   Web of Science ®Google Scholar
• Jin L, Garcia J, Chan E, et al. Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer. Cancer Res. 2017;77(20):5564–5575. doi:10.1158/0008-5472.CAN-17-0314
   PubMed Web of Science ®Google Scholar
• Nakka M, Agoulnik IU, Weigel NL. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol. 2013;45(4):763–772. doi:10.1016/j.biocel.2012.12.012
   Web of Science ®Google Scholar
• He B, Lanz RB, Fiskus W, et al. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014;111(51):18261–18266. doi:10.1073/pnas.1421415111
   Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22. doi:10.1016/j.ccr.2010.05.026
   PubMed Web of Science ®Google Scholar
• Xu J, Wu RC, O’Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer. 2009;9(9):615–630. doi:10.1038/nrc2695
   PubMed Web of Science ®Google Scholar
• Senapati D, Kumari S, Heemers HV. Androgen receptor co-regulation in prostate cancer. Asian J Urol. 2020;7(3):219–232. doi:10.1016/j.ajur.2019.09.005
   Web of Science ®Google Scholar
• Azevedo A, Cunha V, Teixeira AL, Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol. 2011;2(12):384–396. doi:10.5306/wjco.v2.i12.384
   PubMedGoogle Scholar
• Culig Z. Role of the androgen receptor axis in prostate cancer. Urology. 2003;62(5 Suppl 1):21–26. doi:10.1016/S0090-4295(03)00698-8
   Web of Science ®Google Scholar
• Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54(20):5474–5478.
   PubMed Web of Science ®Google Scholar
• Sharma J, Gray KP, Evan C, et al. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014;74(3):225–234. doi:10.1002/pros.22744
   Web of Science ®Google Scholar
• Sharifi N, Auchus RJ. Steroid biosynthesis and prostate cancer. Steroids. 2012;77(7):719–726. doi:10.1016/j.steroids.2012.03.015
   PubMed Web of Science ®Google Scholar
• Titus MA, Gregory CW, Ford OH 3rd, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005;11(12):4365–4371.
   Web of Science ®Google Scholar
• Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10(21):7121–7126. doi:10.1158/1078-0432.CCR-04-0913
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–4454. doi:10.1158/0008-5472.CAN-08-0249
   PubMed Web of Science ®Google Scholar
• Liu C, Lou W, Zhu Y, et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res. 2015;75(7):1413–1422. doi:10.1158/0008-5472.CAN-14-3080
   PubMed Web of Science ®Google Scholar
• Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis--new insights into epithelial-stromal interactions. Cancer Cell. 2007;12(6):495–497. doi:10.1016/j.ccr.2007.11.021
   Web of Science ®Google Scholar
• Lin Y, Wang F. FGF signalling in prostate development, tissue homoeostasis and tumorigenesis. Biosci Rep. 2010;30(5):285–291. doi:10.1042/BSR20100020
   Web of Science ®Google Scholar
• Thomson AA. Role of androgens and fibroblast growth factors in prostatic development. Reproduction. 2001;121(2):187–195. doi:10.1530/rep.0.1210187
   Web of Science ®Google Scholar
• Memarzadeh S, Xin L, Mulholland DJ, et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell. 2007;12(6):572–585. doi:10.1016/j.ccr.2007.11.002
   PubMed Web of Science ®Google Scholar
• Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7(3):165–197. doi:10.1677/erc.0.0070165
   PubMed Web of Science ®Google Scholar
• Thomson AA, Foster BA, Cunha GR. Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. Development. 1997;124(12):2431–2439. doi:10.1242/dev.124.12.2431
   Web of Science ®Google Scholar
• Donjacour AA, Thomson AA, Cunha GR. FGF-10 plays an essential role in the growth of the fetal prostate. Dev Biol. 2003;261(1):39–54. doi:10.1016/S0012-1606(03)00250-1
   Web of Science ®Google Scholar
• Lu W, Luo Y, Kan M, McKeehan WL. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate [published correction appears in J Biol Chem 1999 Sep 24;274(39):28058]. J Biol Chem. 1999;274(18):12827–12834. doi:10.1074/jbc.274.18.12827
   Web of Science ®Google Scholar
• Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst. 2001;93(23):1783–1790. doi:10.1093/jnci/93.23.1783
   PubMed Web of Science ®Google Scholar
• Miki T, Bottaro DP, Fleming TP, et al. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci U S A. 1992;89(1):246–250. doi:10.1073/pnas.89.1.246
   Web of Science ®Google Scholar
• Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol. 1993;13(8):4513–4522. doi:10.1128/mcb.13.8.4513-4522.1993
   PubMed Web of Science ®Google Scholar
• Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate. 2002;52(3):245–252. doi:10.1002/pros.10104
   PubMed Web of Science ®Google Scholar
• Zavadil J, Böttinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764–5774. doi:10.1038/sj.onc.1208927
   PubMed Web of Science ®Google Scholar
• Stone RC, Pastar I, Ojeh N, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res. 2016;365(3):495–506. doi:10.1007/s00441-016-2464-0
   PubMed Web of Science ®Google Scholar
• Yan C, Grimm WA, Garner WL, et al. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am J Pathol. 2010;176(5):2247–2258. doi:10.2353/ajpath.2010.090048
   Web of Science ®Google Scholar
• Acevedo VD, Gangula RD, Freeman KW, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12(6):559–571. doi:10.1016/j.ccr.2007.11.004
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression [published correction appears in Nat Genet 2001 Nov;29(3):351]. Nat Genet. 2001;29(2):117–129.
   PubMed Web of Science ®Google Scholar
• Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate. 1998;37(1):19–29. doi:10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3
   Web of Science ®Google Scholar
• Iruela-Arispe ML, Sage EH. Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-beta 1. J Cell Biochem. 1993;52(4):414–430. doi:10.1002/jcb.240520406
   PubMed Web of Science ®Google Scholar
• Ruscetti F, Varesio L, Ochoa A, Ortaldo J. Pleiotropic effects of transforming growth factor-beta on cells of the immune system. Ann N Y Acad Sci. 1993;685:488–500. doi:10.1111/j.1749-6632.1993.tb35911.x
   PubMed Web of Science ®Google Scholar
• Welch DR, Fabra A, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A. 1990;87(19):7678–7682. doi:10.1073/pnas.87.19.7678
   PubMed Web of Science ®Google Scholar
• Steiner MS, Zhou ZZ, Tonb DC, Barrack ER. Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology. 1994;135(5):2240–2247. doi:10.1210/endo.135.5.7956947
   Web of Science ®Google Scholar
• Derynck R, Zhang YE. Smad-dependent and smad-independent pathways in TGF-beta family signalling. Nature. 2003;425(6958):577–584. doi:10.1038/nature02006
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3):REVIEWS3005. doi:10.1186/gb-2001-2-3-reviews3005
   Web of Science ®Google Scholar
• Jones E, Pu H, Kyprianou N. Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets. 2009;13(2):227–234. doi:10.1517/14728220802705696
   PubMed Web of Science ®Google Scholar
• Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol. 1993;24(1):4–9. doi:10.1016/0046-8177(93)90055-L
   Web of Science ®Google Scholar
• Steiner MS, Anthony CT, Metts J, Moses HL. Prostate cancer cells lose their sensitivity to TGFβI growth inhibition with tumor progression. Urol Oncol. 1995;1(6):252–262. doi:10.1016/1078-1439(96)00028-2
   Google Scholar
• Song K, Wang H, Krebs TL, Kim SJ, Danielpour D. Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res. 2008;68(19):8173–8182. doi:10.1158/0008-5472.CAN-08-2290
   Web of Science ®Google Scholar
• Song K, Wang H, Krebs TL, Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated smad3 activation. EMBO J. 2006;25(1):58–69. doi:10.1038/sj.emboj.7600917
   PubMed Web of Science ®Google Scholar
• Jiao J, Wang S, Qiao R, et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res. 2007;67(13):6083–6091. doi:10.1158/0008-5472.CAN-06-4202
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron. 1992;9(3):383–391. doi:10.1016/0896-6273(92)90177-F
   PubMed Web of Science ®Google Scholar
• Lee YF, Lin WJ, Huang J, et al. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res. 2002;62(21):6039–6044.
   Web of Science ®Google Scholar
• Rybak AP, Bristow RG, Kapoor A. Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget. 2015;6(4):1900–1919. doi:10.18632/oncotarget.2953
   Google Scholar
• Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999;59(2):279–284.
   PubMed Web of Science ®Google Scholar
• Hong SK, Kim JH, Lin MF, Park JI. The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Exp Cell Res. 2011;317(18):2671–2682. doi:10.1016/j.yexcr.2011.08.008
   Web of Science ®Google Scholar
• Mulholland DJ, Kobayashi N, Ruscetti M, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012;72(7):1878–1889. doi:10.1158/0008-5472.CAN-11-3132
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.
   PubMed Web of Science ®Google Scholar
• Wang J, Kobayashi T, Floc’h N, et al. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res. 2012;72(18):4765–4776. doi:10.1158/0008-5472.CAN-12-0820
   PubMed Web of Science ®Google Scholar
• Rybak AP, Ingram AJ, Tang D. Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation. PLoS One. 2013;8(4):e61716. doi:10.1371/journal.pone.0061716
   Web of Science ®Google Scholar
• Yin J, Pollock C, Tracy K, et al. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol. 2007;27(21):7538–7550. doi:10.1128/MCB.00955-07
   PubMed Web of Science ®Google Scholar
• Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res. 2003;63(8):1975–1980.
   Web of Science ®Google Scholar
• Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer. 2004;101(6):1345–1356. doi:10.1002/cncr.20518
   PubMed Web of Science ®Google Scholar
• Kypta RM, Waxman J. Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9(8):418–428. doi:10.1038/nrurol.2012.116
   PubMed Web of Science ®Google Scholar
• Murillo-Garzón V, Kypta R. WNT signalling in prostate cancer. Nat Rev Urol. 2017;14(11):683–696. doi:10.1038/nrurol.2017.144
   PubMed Web of Science ®Google Scholar
• Wan X, Liu J, Lu JF, et al. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res. 2012;18(3):726–736. doi:10.1158/1078-0432.CCR-11-2521
   PubMed Web of Science ®Google Scholar
• de la Taille A, Rubin MA, Chen MW, et al. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res. 2003;9(5):1801–1807.
   Web of Science ®Google Scholar
• Kam Y, Quaranta V. Cadherin-bound beta-catenin feeds into the Wnt pathway upon adherens junctions dissociation: evidence for an intersection between beta-catenin pools. PLoS One. 2009;4(2):e4580. doi:10.1371/journal.pone.0004580
   Web of Science ®Google Scholar
• Shang S, Hua F, Hu ZW. The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017;8(20):33972–33989. doi:10.18632/oncotarget.15687
   PubMedGoogle Scholar
• Wang G, Wang J, Sadar MD. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res. 2008;68(23):9918–9927. doi:10.1158/0008-5472.CAN-08-1718
   PubMed Web of Science ®Google Scholar
• Schweizer L, Rizzo CA, Spires TE, et al. The androgen receptor can signal through Wnt/beta-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol. 2008;9:4. doi:10.1186/1471-2121-9-4
   PubMed Web of Science ®Google Scholar
• Li Y, Wang L, Zhang M, et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 2009;69(8):3332–3338. doi:10.1158/0008-5472.CAN-08-3380
   PubMed Web of Science ®Google Scholar
• Yu X, Wang Y, Jiang M, et al. Activation of beta-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate. 2009;69(3):249–262. doi:10.1002/pros.20877
   PubMed Web of Science ®Google Scholar
• Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/β-catenin activation promotes prostate tumor progression in a mouse model. Oncogene. 2011;30(16):1868–1879. doi:10.1038/onc.2010.560
   PubMed Web of Science ®Google Scholar
• Yang X, Chen MW, Terry S, et al. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells [published correction appears in oncogene. 2006 Jul 13;25(30):4256]. Oncogene. 2006;25(24):3436–3444. doi:10.1038/sj.onc.1209366
   Web of Science ®Google Scholar
• Ciarlo M, Benelli R, Barbieri O, et al. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells [published correction appears in Int J Cancer. 2014 Nov 1;135(9):E9]. Int J Cancer. 2012;131(3):582–590. doi:10.1002/ijc.26402
   Web of Science ®Google Scholar
• Wielenga VJ, Smits R, Korinek V, et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999;154(2):515–523. doi:10.1016/S0002-9440(10)65297-2
   PubMed Web of Science ®Google Scholar
• Mu P, Zhang Z, Benelli M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355(6320):84–88. doi:10.1126/science.aah4307
   PubMed Web of Science ®Google Scholar
• Qi J, Nakayama K, Cardiff RD, et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell. 2010;18(1):23–38. doi:10.1016/j.ccr.2010.05.024
   Web of Science ®Google Scholar
• Yang X, Chen MW, Terry S, et al. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res. 2005;65(12):5263–5271. doi:10.1158/0008-5472.CAN-05-0162
   Web of Science ®Google Scholar
• Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG, Weiss SJ. Canonical Wnt signaling regulates slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci U S A. 2012;109(41):16654–16659. doi:10.1073/pnas.1205822109
   PubMed Web of Science ®Google Scholar
• Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 2003;63(8):1906–1913.
   PubMed Web of Science ®Google Scholar
• Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, Ben-Ze’ev A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, slug, and MAPK. J Cell Biol. 2003;163(4):847–857. doi:10.1083/jcb.200308162
   PubMed Web of Science ®Google Scholar
• Crawford HC, Fingleton BM, Rudolph-Owen LA, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene. 1999;18(18):2883–2891. doi:10.1038/sj.onc.1202627
   PubMed Web of Science ®Google Scholar
• Zhang K, Guo Y, Wang X, et al. WNT/β-catenin directs self-renewal symmetric cell division of hTERThigh prostate cancer stem cells. Cancer Res. 2017;77(9):2534–2547. doi:10.1158/0008-5472.CAN-16-1887
   PubMed Web of Science ®Google Scholar
• Vokes SA, Ji H, Wong WH, McMahon AP. A genome-scale analysis of the cis-regulatory circuitry underlying sonic hedgehog-mediated patterning of the mammalian limb. Genes Dev. 2008;22:2651–2663. doi:10.1101/gad.1693008
   PubMed Web of Science ®Google Scholar
• Shaw A, Bushman W. Hedgehog signaling in the prostate. J Urol. 2007;177:832–838. doi:10.1016/j.juro.2006.10.061
   PubMed Web of Science ®Google Scholar
• Shaw G, Price AM, Ktori E, et al. Hedgehog signalling in androgen independent prostate cancer. Eur Urol. 2008;54(6):1333–1343. doi:10.1016/j.eururo.2008.01.070
   Web of Science ®Google Scholar
• Lee SW, Moskowitz MA, Sims JR. Sonic hedgehog inversely regulates the expression of angiopoietin-1 and angiopoietin-2 in fibroblasts. Int J Mol Med. 2007;19(3):445–451.
   PubMed Web of Science ®Google Scholar
• Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431(7009):707–712. doi:10.1038/nature02962
   PubMed Web of Science ®Google Scholar
• Suzman DL, Antonarakis ES. Clinical implications of hedgehog pathway signaling in prostate cancer. Cancers. 2015;7(4):1983–1993. doi:10.3390/cancers7040871
   Web of Science ®Google Scholar
• Quaglia F, Krishn SR, Wang Y, et al. Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression. PLoS One. 2021;16(1):e0244985. doi:10.1371/journal.pone.0244985
   PubMed Web of Science ®Google Scholar
• Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr Relat Cancer. 2008;15(3):657–664. doi:10.1677/ERC-08-0019
   Web of Science ®Google Scholar
• Cress AE, Rabinovitz I, Zhu W, Nagle RB. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev. 1995;14(3):219–228. doi:10.1007/BF00690293
   Web of Science ®Google Scholar
• Lu H, Wang T, Li J, et al. αvβ6 integrin promotes castrate-resistant prostate cancer through JNK1-mediated activation of androgen receptor. Cancer Res. 2016;76(17):5163–5174. doi:10.1158/0008-5472.CAN-16-0543
   PubMed Web of Science ®Google Scholar
• Juan-Rivera MC, Martínez-Ferrer M. Integrin inhibitors in prostate cancer. Cancers. 2018;10(2):44. doi:10.3390/cancers10020044
   PubMed Web of Science ®Google Scholar
• Shishodia G, Koul S, Koul HK. Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling. Prostate. 2019;79(15):1739–1751. doi:10.1002/pros.23898
   Web of Science ®Google Scholar
• Ni J, Cozzi P, Hao J, et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol. 2013;45(12):2736–2748. doi:10.1016/j.biocel.2013.09.008
   PubMed Web of Science ®Google Scholar
• Jansson KH, Lynch JE, Lepori-Bui N, Czymmek KJ, Duncan RL, Sikes RA. Overexpression of the VSSC-associated CAM, β-2, enhances LNCaP cell metastasis associated behavior. Prostate. 2012;72(10):1080–1092. doi:10.1002/pros.21512
   Web of Science ®Google Scholar
• Daaka Y. G proteins in cancer: the prostate cancer paradigm. Sci STKE. 2004;2004(216):re2. doi:10.1126/stke.2162004re2
   Google Scholar
• Wang W, Chen ZX, Guo DY, Tao YX. Regulation of prostate cancer by hormone-responsive G protein-coupled receptors. Pharmacol Ther. 2018;191:135–147. doi:10.1016/j.pharmthera.2018.06.005
   Web of Science ®Google Scholar
• Pinski J, Xiong S, Wang Q, Stanczyk F, Hawes D, Liu SV. Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer. Prostate. 2011;71(8):892–898. doi:10.1002/pros.21305
   Web of Science ®Google Scholar
• Golbano JM, Lóppez-Aparicio P, Recio MN, Pérez-Albarsanz MA. Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol. 2008;32(4):919–924.
   PubMed Web of Science ®Google Scholar
• Huynh H. Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol. 2002;20(6):1297–1303.
   Web of Science ®Google Scholar
• Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3ʹ-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol. 2007;30(4):905–918.
   Web of Science ®Google Scholar
• Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363(17):1621–1630. doi:10.1056/NEJMoa1001283
   PubMed Web of Science ®Google Scholar
• Feng S, Agoulnik IU, Bogatcheva NV, et al. Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007;13(6):1695–1702. doi:10.1158/1078-0432.CCR-06-2492
   Web of Science ®Google Scholar
• Thompson VC, Hurtado-Coll A, Turbin D, et al. Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer. Prostate. 2010;70(10):1134–1145. doi:10.1002/pros.21148
   Web of Science ®Google Scholar
• Wang H, Jones J, Turner T, et al. Clinical and biological significance of KISS1 expression in prostate cancer. Am J Pathol. 2012;180(3):1170–1178. doi:10.1016/j.ajpath.2011.11.020
   Web of Science ®Google Scholar
• Cassoni P, Ghé C, Marrocco T, et al. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol. 2004;150(2):173–184. doi:10.1530/eje.0.1500173
   Web of Science ®Google Scholar
• Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol. 2003;169(3):1143–1149. doi:10.1097/01.ju.0000042162.08938.27
   Web of Science ®Google Scholar
• Barki-Harrington L, Daaka Y. Bradykinin induced mitogenesis of androgen independent prostate cancer cells. J Urol. 2001;165(6 Pt 1):2121–2125. doi:10.1016/S0022-5347(05)66305-7
   Web of Science ®Google Scholar
• Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer. 2007;97(3):378–383. doi:10.1038/sj.bjc.6603871
   Web of Science ®Google Scholar
• Shariat SF, Andrews B, Kattan MW, et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001;58(6):1008–1015. doi:10.1016/S0090-4295(01)01405-4
   PubMed Web of Science ®Google Scholar
• Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate. 2004;60(3):178–186. doi:10.1002/pros.20045
   Web of Science ®Google Scholar
• Bishop JL, Thaper D, Zoubeidi A. The multifaceted roles of STAT3 signaling in the progression of prostate cancer. Cancers. 2014;6(2):829–859. doi:10.3390/cancers6020829
   PubMed Web of Science ®Google Scholar
• Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 2000;42(3):239–242. doi:10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007;251(2):199–210. doi:10.1016/j.canlet.2006.10.017
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409–416. doi:10.1093/annonc/mdv615
   PubMed Web of Science ®Google Scholar
• Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355–1363. doi:10.1158/2159-8290.CD-13-0310
   PubMed Web of Science ®Google Scholar
• Xu L, Chen X, Shen M, et al. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. Mol Oncol. 2018;12(3):269–286. doi:10.1002/1878-0261.12135
   PubMed Web of Science ®Google Scholar
• Doi T, Ishikawa T, Okayama T, et al. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol Rep. 2017;37(3):1545–1554. doi:10.3892/or.2017.5399
   PubMed Web of Science ®Google Scholar
• Thieu W, Tilki D, de Vere White R, et al. The role of microRNA in castration-resistant prostate cancer. Urol Oncol. 2014;32(5):517–523. doi:10.1016/j.urolonc.2013.11.004
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008;19(1):92–105. doi:10.1101/gr.082701.108
   PubMed Web of Science ®Google Scholar
• Cochetti G, Rossi de Vermandois JA, Maulà V, et al. Role of miRNAs in prostate cancer: do we really know everything? Urol Oncol. 2020;38(7):623–635. doi:10.1016/j.urolonc.2020.03.007
   Web of Science ®Google Scholar
• Kojima S, Goto Y, Naya Y. The roles of microRNAs in the progression of castration-resistant prostate cancer. J Hum Genet. 2017;62(1):25–31. doi:10.1038/jhg.2016.69
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu C-G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257–2261. doi:10.1073/pnas.0510565103
   PubMed Web of Science ®Google Scholar
• Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166–1176. doi:10.1002/ijc.24827
   PubMed Web of Science ®Google Scholar
• Sun T, Yang M, Chen S, et al. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012;72(10):1093–1103. doi:10.1002/pros.22456
   PubMed Web of Science ®Google Scholar
• Shi XB, Ma AH, Xue L, et al. miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src. Cancer Res. 2015;75(24):5309–5317. doi:10.1158/0008-5472.CAN-14-0795
   PubMed Web of Science ®Google Scholar
• Yang X, Bemis L, Su L-J, et al. miR-125b regulation of androgen receptor signaling via modulation of the receptor complex co-repressor NCOR2. Biores Open Access. 2012;1(2):55–62. doi:10.1089/biores.2012.9903
   Google Scholar
• Lin HM, Nikolic I, Yang J, et al. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Sci Rep. 2018;8(7820). doi:10.1038/s41598-018-26050-y
   Web of Science ®Google Scholar
• Choi YJ, Kim HS, Park SH, et al. Phase II Study of dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05). Cancer Res Treat. 2018;50(4):1252–1259. doi:10.4143/crt.2017.438
   PubMed Web of Science ®Google Scholar
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Study of TGF-β receptor inhibitor galunisertib (LY2157299) and enzalutamide in metastatic castration-resistant prostate cancer. NLM identifier: NCT02452008. Available from: https://clinicaltrials.gov/ct2/show/NCT02452008. Accessed June 8, 2021.
   Google Scholar
• Jonsson Comprehensive Cancer Center. Trametinib in treating patients with progressive metastatic hormone-resistant prostate cancer. NLM identifier: NCT02881242. Available from: https://clinicaltrials.gov/ct2/show/NCT02881242. Accessed June 8, 2021.
   Google Scholar
• Pak S, Park S, Kim Y, et al. The small molecule WNT/β-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway [published correction appears in J Exp Clin Cancer Res. 2019 Oct 31;38(1):440]. J Exp Clin Cancer Res. 2019;38(1):342. doi:10.1186/s13046-019-1342-5
   PubMed Web of Science ®Google Scholar
• WntResearch AB. Dose escalating study of foxy-5 in breast-, colon- or prostate cancer patients. NLM identifier: NCT02655952. Available from: https://clinicaltrials.gov/ct2/show/NCT02655952. Accessed June 8, 2021.
   Google Scholar
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. A study of vismodegib in men with metastatic CRPC with accessible metastatic lesions for tumor biopsy. NLM identifier: NCT02115828. Available from: https://clinicaltrials.gov/ct2/show/NCT02115828. Accessed June 8, 2021.
   Google Scholar
• Thaper D, Vahid S, Kaur R, et al. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses enzalutamide-resistant prostate cancer. Sci Rep. 2018;8(1):17307. doi:10.1038/s41598-018-35612-z
   Web of Science ®Google Scholar